Form 4: Stoke Therapeutics Director Receives Stock Option Grant

Director Seth Loring Harrison was granted 17,786 stock options in Stoke Therapeutics, Inc. as part of standard compensation.

Summary

• Director Seth Loring Harrison received a grant of 17,786 stock options on June 3, 2026.
• The options have an exercise price of $29.46 per share.
• The options are set to expire on June 2, 2036.
• The grant vests in full on the earlier of June 3, 2027, or the date of the next annual stockholder meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of the company's common stock.

Future Outlook

The options vest in one year, signaling the director's continued service and commitment to the company's long-term strategic goals.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain experienced board members.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors in mid-cap biotech firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 3, 2027, or the next annual meeting.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Stock Options, Director Compensation